Creative Biolabs Integrates Comprehensive Oncolytic Virus Toxicology Studies into Preclinical In Vivo Study Service
December 02, 2022 at 09:01
With R&D expertise in oncolytic virus research, Creative Biolabs now upgrades a new range of oncolytic virus preclinical study services, especially toxicology study service, covering virus shedding study, clinical pathology, histopathology, and off-target toxicity.
With the emerging concerns of patient safety, the discovery of treatments as safe as possible has long been a priority. Oncolytic virotherapy, an emerging treatment for cancer, demonstrates the growing interest in this field. Although presenting a number of positive therapeutic features in solid tumors over the past decade, the efficacy and safety of oncolytic viruses (OVs) in intermediate to advanced solid tumors remain controversial, which calls for enhanced and comprehensive studies on the safety evaluation.
With R&D expertise in OV research, Creative Biolabs now upgrades a new range of oncolytic virus preclinical study services to help prove the safety and efficacy of the potential OV therapeutics. Especially, the scientist team highlights services for OV toxicology studies by introducing long-term, robust, and effective analytical tools and platforms.
-- Oncolytic Virus Shedding Study
-- Clinical Observations (body weight, appetite, morbidity/mortality, etc.)
-- Clinical Pathology (hematology, coagulation, clinical chemistry, urinalysis, etc.)
-- Gross Organ Pathology (weight of brain, liver, kidney, lung, heart, spleen, testes, and ovaries)
-- Histopathology (brain, liver, kidney, lung, heart, spleen, testes, ovaries, bone marrow, and quadriceps muscle)
-- Transgene Specific Toxicity Study
-- Off-Target Toxicity Study
To support the safety of the proposed clinical investigation of OVs, specialists at Creative Biolabs provide cover-all in vivo toxicology studies considering the nature of virus species, engineered elements, animal model establishment, targeted disease, and administration route. The team manager of highly experienced scientific and quality assurance professionals is always ready to hear clients' thoughts and actively push the projects through all phases of preclinical and clinical development.
"To comprehensively assess the safety and effect of a new therapeutics can be a daunting task if not done in an organized or simplified manner. Our expert scientists and dedicated team members are here to make sure you get the backing and tools you need to be most successful in your research endeavors as you drive to the discovery that will shape the future." said a senior scientist at Creative Biolabs.
More information about OV services and products can be found at https://www.creative-biolabs.com/oncolytic-virus.About Creative Biolabs
Empowered by leading technology and years of experience in biomedical science, Creative Biolabs is dedicated to offering comprehensive, end-to-end oncolytic virus therapy development services. The whole pipeline covers OV engineering, in vitro validation study, in vivo preclinical study, and disease-specific oncolytic virotherapy development. A list of pre-made OV products and oncolytic adenovirus construction kits is also available.